PCA demonstrated that some specific inflammatory mediators (e.g., IL-6, CXCL10, GDF-15, GM-CSF, CCL2) were the strongest determinants of the variance apparent between COVID-19 patients (fig. This evidence concerns the gene CCL2 and COVID-19.